Novartis Korea to close down Respiratory BU next month
By | translator Alice Kang
22.09.14 06:18:11
가나다라
0
Reorganizes into 5 divisions through mergers and closures of business units... will get rid of Respiratory products
May hand over licenses of products that render insignificant sales, such as Atectura Enerzair, etc.
Respiratory unit personnel to be reassigned to other units...some apply for early retirement
According to industry sources on the 14th, Novartis Korea’s Respiratory Business Unit will be officially closed down next month as part of the company’s large-scale reorganization in progress at the global level.
Currently, Novartis Korea is operated in two business units - Pharmaceuticals BU and Oncology BU. The Pharmaceuticals BU consists of Cardiovascular & Metabolic Diseases; Autoimmunity, Transplantation & Inflammatory Diseases; Skin Diseases. The global reorganization is being made to first integrate the Pharmaceuticals and Oncology Business Units and the
(same@dailypharm.com)
If you want to see the full article, please JOIN US (click)